Unlock instant, AI-driven research and patent intelligence for your innovation.

Gene diagnosis composite for predicting aspirin resistance probability of STEMI (segment elevation myocardial infarction) patient

A technology of myocardial infarction and aspirin, applied in the biological field, can solve problems such as adverse cardiovascular events, increased bleeding risk, and endangering the lives of patients

Inactive Publication Date: 2018-06-01
周林飞
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, once clopidogrel or aspirin resistance occurs, it will lead to the occurrence of adverse cardiovascular events after PCI treatment, greatly increase the risk of bleeding, and even endanger the lives of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene diagnosis composite for predicting aspirin resistance probability of STEMI (segment elevation myocardial infarction) patient
  • Gene diagnosis composite for predicting aspirin resistance probability of STEMI (segment elevation myocardial infarction) patient
  • Gene diagnosis composite for predicting aspirin resistance probability of STEMI (segment elevation myocardial infarction) patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: circRNAs composition and method for predicting aspirin resistance in patients with stable angina pectoris

[0060] 1. Experimental samples

[0061]Patients with coronary heart disease who were scheduled to undergo PCI in Hunan Provincial People's Hospital from March 2015 to June 2017 were selected, and patients with coronary heart disease were divided into stable angina group according to preoperative diagnosis (coronary angiography and electrocardiogram, etc.) SAP group), unstable angina group (UA group), ST-segment elevation myocardial infarction group (STEMI group) and non-ST-segment elevation myocardial infarction group (NSTEMI group). Pre-treatment with 300 mg of aspirin enteric-coated tablets (Bayer) was given before the operation, and the maximum platelet aggregation rate (MPAR) induced by 5 μM adenosine diphosphate was detected before and 12 hours after taking the drug. Relative expression of target circRNAs. Aspirin resistance was defined as MPAR≤1...

Embodiment 2

[0092] Example 2: circRNAs composition and method for predicting aspirin resistance in patients with unstable angina pectoris

[0093] 1. Experimental samples

[0094] With embodiment 1.

[0095] 2. Experimental method

[0096] 1. Total RNA extraction and quality detection

[0097] According to the instructions of the TaKaRa RNAiso Blood kit, 250 μL of plasma was collected from each sample, and the total RNA in the plasma sample was extracted. Use a spectrophotometer to measure the optical density D (260) and D (280) values ​​of the total RNA, use the D (260) value to calculate its concentration, and calculate the D (260) / D (280) value to detect its purity, D (260 ) / D(280) value in the range of 1.8 to 2.1 is considered qualified.

[0098] 2. Detection of target circRNAs by real-time fluorescent quantitative PCR

[0099]Follow the instructions of the PrimeScript RT reagent Kit with gDNAEraser kit. The real-time fluorescent quantitative PCR primers for the target circRNAs ...

Embodiment 3

[0121] Example 3: circRNAs composition and method for predicting aspirin resistance in patients with ST-segment elevation myocardial infarction

[0122] 1. Experimental samples

[0123] With embodiment 1.

[0124] 2. Experimental method

[0125] 1. Total RNA extraction and quality inspection

[0126] According to the instructions of the TaKaRa RNAiso Blood kit, 250 μL of plasma was collected from each sample, and the total RNA in the plasma sample was extracted. Use a spectrophotometer to measure the optical density D (260) and D (280) values ​​of the total RNA, use the D (260) value to calculate its concentration, and calculate the D (260) / D (280) value to detect its purity, D (260 ) / D(280) value in the range of 1.8 to 2.1 is considered qualified.

[0127] 2. Detection of target circRNAs by real-time fluorescence quantitative PCR

[0128] Follow the instructions of the PrimeScript RT reagent Kit with gDNAEraser kit. The real-time fluorescent quantitative PCR primers for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a gene diagnosis composite for predicting the aspirin resistance probability of an STEMI (segment elevation myocardial infarction) patient. The gene diagnosis composite finds that circRNAs (Ribonucleic Acids) can be used for predicting whether different types of coronary heart diseases are subjected to the aspirin resistance or not, and a risk for different types of coronary heart disease patients to be subjected to the aspirin resistance can be evaluated in an early stage before a PCI (Percutaneous Transluminal Coronary Intervention) surgery to serve as a reference basis for carrying out the PCI surgery or not or an emergency plan for preventing from the aspirin resistance after the PCI surgery as early as possible.

Description

technical field [0001] The invention belongs to the field of biology, and in particular relates to the prediction of antiplatelet drug resistance in patients with different types of coronary heart disease. Background technique [0002] Platelet activation and aggregation are involved in the entire development process of coronary heart disease. Antiplatelet therapy based on aspirin and clopidogrel is the cornerstone of drug treatment after interventional therapy for coronary heart disease. Administration of aspirin and clopidogrel after PCI can delay vascular endothelialization, delay restenosis and thrombosis, and significantly reduce the risk of cardiovascular adverse events, especially stent thrombosis. Clinical evidence shows that for patients with different types of coronary heart disease, antiplatelet therapy after PCI can significantly reduce the occurrence of adverse cardiovascular events and reduce the risk of bleeding. [0003] In recent years, studies have found t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/158C12Q2600/178
Inventor 周林飞姜振东董杏林
Owner 周林飞
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com